Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Bacterial Vaginosis Drugs Market 2018, Forecast to 2023

  • receipt Report ID : 136882
  • calendar_today Published On: Jan, 2019
  • file_copy Pages: 116
  • list Pharmaceuticals and Healthcare

Bacterial vaginosis is an imbalance of "good" and "bad" bacteria in the vagina, with there being more bad bacteria. Causes of an imbalance of bacteria can be caused by multiple sex partners and douching. Symptoms include odor, discharge, burning, and itching. Treatments for bacterial vaginosis include the use of probiotics and medication. Common drug classes include lincosamide antibiotics and nitroimidazole antibiotics.

Scope of the Report:

This report focuses on the Bacterial Vaginosis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

One driver in the market is unmet demand in BV treatment market. Unmet demand in the treatment of BV has created great opportunity for the market players. There is huge unmet need in the treatment of BV, especially the recurrent form of the disease. BV is the most common vaginal infection in the women of child bearing age group. Despite being highly prevalent in nature, little has been done in the field. When left untreated, it may lead to severe infections, especially in the case of pregnant women such as preterm births. rising awareness about women's health as one of the primary growth factors for the bacterial vaginosis drugs market. Owing to recent advancements in healthcare and the initiatives taken by the government and non-government organizations to increase the awareness about health of women, the demand for pharmaceuticals related to disorders in women will witness a significant increase in the coming years. Additionally, support from government is also a key driver.

The worldwide market for Bacterial Vaginosis Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.

Market Segment by Manufacturers, this report covers

Bayer

Pfizer

Sanofi

Starpharma Holdings

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Oral

Topical

Market Segment by Applications, can be divided into

Pelvic Inflammatory Disease

Preterm Delivery of Infants

Urinary Tract Infection

Sexually Transmitted Diseases (STD)

There are 15 Chapters to deeply display the global Bacterial Vaginosis Drugs market.

Chapter 1, to describe Bacterial Vaginosis Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Bacterial Vaginosis Drugs, with sales, revenue, and price of Bacterial Vaginosis Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Bacterial Vaginosis Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Bacterial Vaginosis Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Bacterial Vaginosis Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Bacterial Vaginosis Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Oral

1.2.2 Topical

1.3 Market Analysis by Applications

1.3.1 Pelvic Inflammatory Disease

1.3.2 Preterm Delivery of Infants

1.3.3 Urinary Tract Infection

1.3.4 Sexually Transmitted Diseases (STD)

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Bayer

2.1.1 Business Overview

2.1.1.1 Bayer Description

2.1.1.2 Bayer Headquarter, Main Business and Finance Overview

2.1.2 Bayer Bacterial Vaginosis Drugs Product Introduction

2.1.2.1 Bacterial Vaginosis Drugs Production Bases, Sales Regions and Major Competitors

2.1.2.2 Bacterial Vaginosis Drugs Product Information

2.1.3 Bayer Bacterial Vaginosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.1.3.1 Bayer Bacterial Vaginosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.1.3.2 Global Bayer Bacterial Vaginosis Drugs Market Share in 2017

2.2 Pfizer

2.2.1 Business Overview

2.2.1.1 Pfizer Description

2.2.1.2 Pfizer Headquarter, Main Business and Finance Overview

2.2.2 Pfizer Bacterial Vaginosis Drugs Product Introduction

2.2.2.1 Bacterial Vaginosis Drugs Production Bases, Sales Regions and Major Competitors

2.2.2.2 Bacterial Vaginosis Drugs Product Information

2.2.3 Pfizer Bacterial Vaginosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2.3.1 Pfizer Bacterial Vaginosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2.3.2 Global Pfizer Bacterial Vaginosis Drugs Market Share in 2017

2.3 Sanofi

2.3.1 Business Overview

2.3.1.1 Sanofi Description

2.3.1.2 Sanofi Headquarter, Main Business and Finance Overview

2.3.2 Sanofi Bacterial Vaginosis Drugs Product Introduction

2.3.2.1 Bacterial Vaginosis Drugs Production Bases, Sales Regions and Major Competitors

2.3.2.2 Bacterial Vaginosis Drugs Product Information

2.3.3 Sanofi Bacterial Vaginosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3.3.1 Sanofi Bacterial Vaginosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3.3.2 Global Sanofi Bacterial Vaginosis Drugs Market Share in 2017

2.4 Starpharma Holdings

2.4.1 Business Overview

2.4.1.1 Starpharma Holdings Description

2.4.1.2 Starpharma Holdings Headquarter, Main Business and Finance Overview

2.4.2 Starpharma Holdings Bacterial Vaginosis Drugs Product Introduction

2.4.2.1 Bacterial Vaginosis Drugs Production Bases, Sales Regions and Major Competitors

2.4.2.2 Bacterial Vaginosis Drugs Product Information

2.4.3 Starpharma Holdings Bacterial Vaginosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4.3.1 Starpharma Holdings Bacterial Vaginosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4.3.2 Global Starpharma Holdings Bacterial Vaginosis Drugs Market Share in 2017

3 Global Bacterial Vaginosis Drugs Market Competition, by Manufacturer

3.1 Global Bacterial Vaginosis Drugs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Bacterial Vaginosis Drugs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Global Bacterial Vaginosis Drugs Price by Manufacturer (2016-2017)

3.4 Market Concentration Rate

3.4.1 Top 3 Bacterial Vaginosis Drugs Manufacturer Market Share in 2017

3.4.2 Top 5 Bacterial Vaginosis Drugs Manufacturer Market Share in 2017

3.5 Market Competition Trend

4 Global Bacterial Vaginosis Drugs Market Analysis by Regions

4.1 Global Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Regions

4.1.1 Global Bacterial Vaginosis Drugs Sales by Regions (2013-2018)

4.1.2 Global Bacterial Vaginosis Drugs Revenue by Regions (2013-2018)

4.2 North America Bacterial Vaginosis Drugs Sales, Revenue and Growth Rate (2013-2018)

4.3 Europe Bacterial Vaginosis Drugs Sales, Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Bacterial Vaginosis Drugs Sales, Revenue and Growth Rate (2013-2018)

4.5 South America Bacterial Vaginosis Drugs Sales, Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Bacterial Vaginosis Drugs Sales, Revenue and Growth Rate (2013-2018)

5 North America Bacterial Vaginosis Drugs by Countries, Type, Application and Manufacturers

5.1 North America Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Countries

5.1.1 North America Bacterial Vaginosis Drugs Sales by Countries (2013-2018)

5.1.2 North America Bacterial Vaginosis Drugs Revenue by Countries (2013-2018)

5.1.3 United States Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

5.1.4 Canada Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

5.1.5 Mexico Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

5.2 North America Bacterial Vaginosis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)

5.2.1 North America Bacterial Vaginosis Drugs Sales by Manufacturers (2016-2017)

5.2.2 North America Bacterial Vaginosis Drugs Revenue by Manufacturers (2016-2017)

5.3 North America Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Type (2013-2018)

5.3.1 North America Bacterial Vaginosis Drugs Sales and Sales Share by Type (2013-2018)

5.3.2 North America Bacterial Vaginosis Drugs Revenue and Revenue Share by Type (2013-2018)

5.4 North America Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Application (2013-2018)

5.4.1 North America Bacterial Vaginosis Drugs Sales and Sales Share by Application (2013-2018)

5.4.2 North America Bacterial Vaginosis Drugs Revenue and Revenue Share by Application (2013-2018)

6 Europe Bacterial Vaginosis Drugs by Countries, Type, Application and Manufacturers

6.1 Europe Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Countries

6.1.1 Europe Bacterial Vaginosis Drugs Sales by Countries (2013-2018)

6.1.2 Europe Bacterial Vaginosis Drugs Revenue by Countries (2013-2018)

6.1.3 Germany Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

6.1.4 UK Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

6.1.5 France Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

6.1.6 Russia Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

6.1.7 Italy Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

6.2 Europe Bacterial Vaginosis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)

6.2.1 Europe Bacterial Vaginosis Drugs Sales by Manufacturers (2016-2017)

6.2.2 Europe Bacterial Vaginosis Drugs Revenue by Manufacturers (2016-2017)

6.3 Europe Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Type (2013-2018)

6.3.1 Europe Bacterial Vaginosis Drugs Sales and Sales Share by Type (2013-2018)

6.3.2 Europe Bacterial Vaginosis Drugs Revenue and Revenue Share by Type (2013-2018)

6.4 Europe Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Application (2013-2018)

6.4.1 Europe Bacterial Vaginosis Drugs Sales and Sales Share by Application (2013-2018)

6.4.2 Europe Bacterial Vaginosis Drugs Revenue and Revenue Share by Application (2013-2018)

7 Asia-Pacific Bacterial Vaginosis Drugs by Countries, Type, Application and Manufacturers

7.1 Asia-Pacific Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Bacterial Vaginosis Drugs Sales by Countries (2013-2018)

7.1.2 Asia-Pacific Bacterial Vaginosis Drugs Revenue by Countries (2013-2018)

7.1.3 China Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

7.1.4 Japan Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

7.1.5 Korea Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

7.1.6 India Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

7.1.7 Southeast Asia Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

7.2 Asia-Pacific Bacterial Vaginosis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)

7.2.1 Asia-Pacific Bacterial Vaginosis Drugs Sales by Manufacturers (2016-2017)

7.2.2 Asia-Pacific Bacterial Vaginosis Drugs Revenue by Manufacturers (2016-2017)

7.3 Asia-Pacific Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Type (2013-2018)

7.3.1 Asia-Pacific Bacterial Vaginosis Drugs Sales and Sales Share by Type (2013-2018)

7.3.2 Asia-Pacific Bacterial Vaginosis Drugs Revenue and Revenue Share by Type (2013-2018)

7.4 Asia-Pacific Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Application (2013-2018)

7.4.1 Asia-Pacific Bacterial Vaginosis Drugs Sales and Sales Share by Application (2013-2018)

7.4.2 Asia-Pacific Bacterial Vaginosis Drugs Revenue and Revenue Share by Application (2013-2018)

8 South America Bacterial Vaginosis Drugs by Countries, Type, Application and Manufacturers

8.1 South America Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Countries

8.1.1 South America Bacterial Vaginosis Drugs Sales by Countries (2013-2018)

8.1.2 South America Bacterial Vaginosis Drugs Revenue by Countries (2013-2018)

8.1.3 Brazil Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

8.1.4 Argentina Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

8.1.5 Colombia Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

8.2 South America Bacterial Vaginosis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)

8.2.1 South America Bacterial Vaginosis Drugs Sales by Manufacturers (2016-2017)

8.2.2 South America Bacterial Vaginosis Drugs Revenue by Manufacturers (2016-2017)

8.3 South America Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Type (2013-2018)

8.3.1 South America Bacterial Vaginosis Drugs Sales and Sales Share by Type (2013-2018)

8.3.2 South America Bacterial Vaginosis Drugs Revenue and Revenue Share by Type (2013-2018)

8.4 South America Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Application (2013-2018)

8.4.1 South America Bacterial Vaginosis Drugs Sales and Sales Share by Application (2013-2018)

8.4.2 South America Bacterial Vaginosis Drugs Revenue and Revenue Share by Application (2013-2018)

9 Middle East and Africa Bacterial Vaginosis Drugs by Countries, Type, Application and Manufacturers

9.1 Middle East and Africa Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Bacterial Vaginosis Drugs Sales by Countries (2013-2018)

9.1.2 Middle East and Africa Bacterial Vaginosis Drugs Revenue by Countries (2013-2018)

9.1.3 Saudi Arabia Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

9.1.4 UAE Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

9.1.5 Egypt Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

9.1.6 Nigeria Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

9.1.7 South Africa Bacterial Vaginosis Drugs Sales and Growth Rate (2013-2018)

9.2 Middle East and Africa Bacterial Vaginosis Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)

9.2.1 Middle East and Africa Bacterial Vaginosis Drugs Sales by Manufacturers (2016-2017)

9.2.2 Middle East and Africa Bacterial Vaginosis Drugs Revenue by Manufacturers (2016-2017)

9.3 Middle East and Africa Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Type (2013-2018)

9.3.1 Middle East and Africa Bacterial Vaginosis Drugs Sales and Sales Share by Type (2013-2018)

9.3.1 Middle East and Africa Bacterial Vaginosis Drugs Revenue and Revenue Share by Type (2013-2018)

9.4 Middle East and Africa Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Application (2013-2018)

9.4.1 Middle East and Africa Bacterial Vaginosis Drugs Sales and Sales Share by Application (2013-2018)

9.4.2 Middle East and Africa Bacterial Vaginosis Drugs Revenue and Revenue Share by Application (2013-2018)

10 Global Bacterial Vaginosis Drugs Market Segment by Type

10.1 Global Bacterial Vaginosis Drugs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Bacterial Vaginosis Drugs Sales and Market Share by Type (2013-2018)

10.1.2 Global Bacterial Vaginosis Drugs Revenue and Market Share by Type (2013-2018)

10.2 Oral Sales Growth and Price

10.2.1 Global Oral Sales Growth (2013-2018)

10.2.2 Global Oral Price (2013-2018)

10.3 Topical Sales Growth and Price

10.3.1 Global Topical Sales Growth (2013-2018)

10.3.2 Global Topical Price (2013-2018)

11 Global Bacterial Vaginosis Drugs Market Segment by Application

11.1 Global Bacterial Vaginosis Drugs Sales Market Share by Application (2013-2018)

11.2 Pelvic Inflammatory Disease Sales Growth (2013-2018)

11.3 Preterm Delivery of Infants Sales Growth (2013-2018)

11.4 Urinary Tract Infection Sales Growth (2013-2018)

11.5 Sexually Transmitted Diseases (STD) Sales Growth (2013-2018)

12 Bacterial Vaginosis Drugs Market Forecast (2018-2023)

12.1 Global Bacterial Vaginosis Drugs Sales, Revenue and Growth Rate (2018-2023)

12.2 Bacterial Vaginosis Drugs Market Forecast by Regions (2018-2023)

12.2.1 North America Bacterial Vaginosis Drugs Market Forecast (2018-2023)

12.2.2 Europe Bacterial Vaginosis Drugs Market Forecast (2018-2023)

12.2.3 Asia-Pacific Bacterial Vaginosis Drugs Market Forecast (2018-2023)

12.2.4 South America Bacterial Vaginosis Drugs Market Forecast (2018-2023)

12.2.5 Middle East and Africa Bacterial Vaginosis Drugs Market Forecast (2018-2023)

12.3 Bacterial Vaginosis Drugs Market Forecast by Type (2018-2023)

12.3.1 Global Bacterial Vaginosis Drugs Sales Forecast by Type (2018-2023)

12.3.2 Global Bacterial Vaginosis Drugs Market Share Forecast by Type (2018-2023)

12.4 Bacterial Vaginosis Drugs Market Forecast by Application (2018-2023)

12.4.1 Global Bacterial Vaginosis Drugs Sales Forecast by Application (2018-2023)

12.4.2 Global Bacterial Vaginosis Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Bacterial Vaginosis Drugs Picture

Table Product Specifications of Bacterial Vaginosis Drugs

Figure Global Bacterial Vaginosis Drugs CAGR (%), Y-o-Y Growth (&) and Ma

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery